利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

53 条记录 (耗时 0.034 秒)

    Uses of secretagogues like ghrelin in cancer cachexia and for stimulating appetite
    1.
    发明申请
    Uses of secretagogues like ghrelin in cancer cachexia and for stimulating appetite 审中-公开
    使用促分泌素如生长素释放肽在癌症恶病质和刺激食欲

    公开(公告)号：US20070037751A1

    公开(公告)日：2007-02-15

    申请号：US10567406

    申请日：2004-08-06

    申请人： Birgitte Lange ,  Christian Hansen ,  Henrik Nilsson

    发明人： Birgitte Lange ,  Christian Hansen ,  Henrik Nilsson

    IPC分类号： A61K38/08 ,  A61K38/05 ,  A61K38/06

    CPC分类号： C07K14/575 ,  A61K38/00

    摘要： The present invention relates, in one aspect, to the use of a secretagogue compound for the preparation of a medicament for the prophylaxis or treatment of cancer cachexia in an individual in need of such treatment. In another aspect, the present invention relates to the use of a ghrelin-like compound for the preparation of a medicament for prophylaxis or treatment of cachexia in an individual by administering a subcutaneous dosage of said medicament to the individual. In a further aspect, the present invention relates to the use of a ghrelin-like compound or a pharmaceutically acceptable salt thereof for the preparation of a medicament for stimulation of appetite in an individual by administering a subcutaneous dosage of said medicament to the individual. Furthermore, the present invention relates to a number of new ghrelin-like compounds and uses thereof, as well as to pharmaceutical compositions and medical packaging comprising the new ghrelin-like compounds.

    摘要翻译： 本发明在一个方面涉及促分泌素化合物在制备用于预防或治疗需要这种治疗的个体中的癌症恶病质的药物中的用途。 另一方面，本发明涉及生长素释放肽样化合物在制备用于预防或治疗个体中恶病质的药物中的用途，其通过向个体施用皮下剂量的所述药物。 在另一方面，本发明涉及生长素释放肽样化合物或其药学上可接受的盐在制备用于通过向个体施用所述药物的皮下剂量来刺激个体中的食欲的药物中的用途。 此外，本发明涉及许多新的生长素释放肽样化合物及其用途，以及包含新的生长素释放肽样化合物的药物组合物和医药包装。

    USE OF A GLP-1 MOLECULE FOR TREATMENT OF BILIARY DYSKINESIA AND/OR BILIARY PAIN/DISCOMFORT
    2.
    发明申请
    USE OF A GLP-1 MOLECULE FOR TREATMENT OF BILIARY DYSKINESIA AND/OR BILIARY PAIN/DISCOMFORT 审中-公开
    用于治疗胆汁淤积症和/或胆汁淤积/分泌的GLP-1分子的使用

    公开(公告)号：US20090181887A1

    公开(公告)日：2009-07-16

    申请号：US12066178

    申请日：2006-09-06

    申请人： Christian Hansen ,  Henrik Nilsson ,  Hans T. Schambye ,  Tina Geritz Nielsen

    发明人： Christian Hansen ,  Henrik Nilsson ,  Hans T. Schambye ,  Tina Geritz Nielsen

    IPC分类号： A61K38/22 ,  A61P25/00 ,  G01N33/566

    CPC分类号： A61K38/26 ,  G01N2333/605 ,  G01N2500/02 ,  G01N2800/08 ,  Y02A50/49

    摘要： The present invention relates to molecules, compositions and methods suitable for the treatment or prevention of biliary dyskinesia and/or pain and/or discomfort originating from the biliary tree. The peptide hormone glucagon-like peptide-1 (GLP-1) has both anti-secretory effects and smooth muscle relaxatory properties in the gastrointestinal tract. GLP-1 exists in several forms, where the natural occurring GLP-1 molecules are GLP-1 (1-37), GLP-1 (7-37), and the amidated versions GLP-1 (1-36)amide, GLP-1 (7-36)amide. Other molecules capable of binding to and activating the GLP-1 receptor is herein included in the tern GLP-1 molecules. GLP-1 molecules may be naturally occurring or homologues of GLP-1 having one or more amino acid substitutions or modifications. The GLP-1 molecules are used for the manufacture of a medicament for the treatment or prevention of biliary dyskinesia and/or pain and/or discomfort originating from the biliary tree.

    摘要翻译： 本发明涉及适用于治疗或预防来自胆道树的胆汁运动障碍和/或疼痛和/或不适的分子，组合物和方法。 肽激素胰高血糖素样肽-1（GLP-1）在胃肠道中具有抗分泌作用和平滑肌松弛性质。 GLP-1以几种形式存在，其中天然存在的GLP-1分子是GLP-1（1-37），GLP-1（7-37）和酰胺化型GLP-1（1-36）酰胺，GLP -1（7-36）酰胺。 在GLP-1分子中包括能够结合并激活GLP-1受体的其它分子。 GLP-1分子可以是具有一个或多个氨基酸取代或修饰的GLP-1的天然存在或同源物。 GLP-1分子用于制造用于治疗或预防胆汁运动障碍和/或来自胆道树的疼痛和/或不适的药物。

    WATER-SOLUBLE STRONTIUM SALTS FOR USE IN TREATMENT OF CARTILAGE AND/OR BONE CONDITIONS
    4.
    发明申请
    WATER-SOLUBLE STRONTIUM SALTS FOR USE IN TREATMENT OF CARTILAGE AND/OR BONE CONDITIONS 失效
    用于治疗骨质疏松症和/或骨质疏松症的水溶性UM条

    公开(公告)号：US20100048697A1

    公开(公告)日：2010-02-25

    申请号：US12535053

    申请日：2009-08-04

    申请人： Christian Hansen ,  Henrik Nilsson ,  Stephan Christgau ,  Jens E.T. Andersen

    发明人： Christian Hansen ,  Henrik Nilsson ,  Stephan Christgau ,  Jens E.T. Andersen

    IPC分类号： A61K31/28

    CPC分类号： A61K33/24 ,  C07C55/08 ,  C07C55/10 ,  C07C57/145 ,  C07C59/08 ,  C07C59/19 ,  C07C59/347

    摘要： Compounds and pharmaceutical compositions for use in the treatment and/or prophylaxis of cartilage and/or bone conditions and for methods of treating such condition. The compounds are salts of strontium that have a water-solubility of from about 1 g/l to about 100 g/l at room temperature, especially amino acid salts of strontium or dicarboxylic acid salts of strontium. Examples of novel water-soluble strontium salts are e.g. strontium glutamate and strontium alpha-ketoglutarate. The present invention also relates to an improved method for preparing the strontium salt of glutamic acid.

    摘要翻译： 用于治疗和/或预防软骨和/或骨骼状况的化合物和药物组合物以及治疗这种病症的方法。 化合物是在室温下具有约1g / l至约100g / l水溶性的锶盐，特别是锶的锶或二羧酸盐的氨基酸盐。 新的水溶性锶盐的实例是例如。 谷氨酸锶和α-酮戊二酸锶。 本发明还涉及一种制备谷氨酸锶盐的改进方法。

    Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions
    5.
    发明授权
    Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions 失效
    用于治疗软骨和/或骨骼状况的水溶性锶盐

    公开(公告)号：US07595342B2

    公开(公告)日：2009-09-29

    申请号：US11269289

    申请日：2005-11-07

    申请人： Christian Hansen ,  Henrik Nilsson ,  Stephan Christgau ,  Jens E.T. Andersen

    发明人： Christian Hansen ,  Henrik Nilsson ,  Stephan Christgau ,  Jens E.T. Andersen

    IPC分类号： A61K31/19

    CPC分类号： A61K33/24 ,  C07C55/08 ,  C07C55/10 ,  C07C57/145 ,  C07C59/08 ,  C07C59/19 ,  C07C59/347

    摘要： Compounds and pharmaceutical compositions for use in the treatment and/or prophylaxis of cartilage and/or bone conditions and for methods of treating such condition. The compounds are salts of strontium that have a water-solubility of from about 1 g/l to about 100 g/l at room temperature, especially amino acid salts of strontium or dicarboxylic acid salts of strontium. Examples of novel water-soluble strontium salts are e.g. strontium glutamate and strontium alpha-ketoglutarate. The present invention also relates to an improved method for preparing the strontium salt of glutamic acid.

    摘要翻译： 用于治疗和/或预防软骨和/或骨骼状况的化合物和药物组合物以及治疗这种病症的方法。 化合物是在室温下具有约1g / l至约100g / l水溶性的锶盐，特别是锶的锶或二羧酸盐的氨基酸盐。 新的水溶性锶盐的实例是例如。 谷氨酸锶和α-酮戊二酸锶。 本发明还涉及一种制备谷氨酸锶盐的改进方法。

    PHARMACEUTICAL PREPARATIONS OF A GLP-1 MOLECULE AND AN ANTI-EMETIC DRUG
    8.
    发明申请
    PHARMACEUTICAL PREPARATIONS OF A GLP-1 MOLECULE AND AN ANTI-EMETIC DRUG 审中-公开
    GLP-1分子和抗静脉药物的药物制备

    公开(公告)号：US20090305964A1

    公开(公告)日：2009-12-10

    申请号：US11912051

    申请日：2006-04-21

    申请人： Hans T. Schambye ,  Henrik Nilsson ,  Christian Hansen

    发明人： Hans T. Schambye ,  Henrik Nilsson ,  Christian Hansen

    IPC分类号： A61K38/22

    CPC分类号： A61K45/06 ,  A61K38/26 ,  A61K2300/00

    摘要： The present invention relates to a kit of parts comprising a GLP-1 molecule and an anti-emetic drug, said kit of parts being suitable for separate, sequential or/and simultaneous administration to a subject, preferably a human being. Also provided are combinations of GLP-1 or a GLP-1 analog with one or more anti-emetic drugs, as well as uses of the combinations in the manufacture of medicaments.

    摘要翻译： 本发明涉及包含GLP-1分子和抗呕吐药物的试剂盒，所述试剂盒适用于对受试者，优选人类的单独，连续或/和同时施用。 还提供了GLP-1或GLP-1类似物与一种或多种抗呕吐药物的组合，以及组合制备药物的用途。

    Method of Improving Treatments in Rheumatic and Arthritic Diseases
    9.
    发明申请
    Method of Improving Treatments in Rheumatic and Arthritic Diseases 审中-公开
    改善风湿性关节炎疾病治疗方法

    公开(公告)号：US20090035315A1

    公开(公告)日：2009-02-05

    申请号：US11629613

    申请日：2005-06-17

    申请人： Stephan Christgau ,  Christian Hansen ,  Henrik Nilsson

    发明人： Stephan Christgau ,  Christian Hansen ,  Henrik Nilsson

    IPC分类号： A61K39/395 ,  A61K31/662 ,  A61K31/351 ,  A61K31/715 ,  A61K31/724 ,  A61K31/192 ,  A61K31/18 ,  A61K31/167 ,  A61K31/60 ,  A61K31/235 ,  A61K31/5415 ,  A61K31/56 ,  A61K38/00 ,  A61K31/415

    CPC分类号： A61K31/519 ,  A61K31/28 ,  A61K31/403 ,  A61K31/573 ,  A61K31/65 ,  A61K31/663 ,  A61K31/7008 ,  A61K31/737 ,  A61K33/24 ,  A61K45/06 ,  A61K2300/00

    摘要： Improved treatments of joint diseases, such as, e.g. osteoarthritis and rheumatoid arthritis, and pain, wherein a strontium-containing compound is administered alone or in combination with one or more second therapeutically and/or prophylactically active substances, selected from the group consisting of bisphosphonates, glucosamine, pallitative agents, analgesic agents, disease modifying anti-rheumatic compounds (DMARDs), selective estrogen receptor modulators (SERMs), aromatase inhibitors, non-steroidal anti-inflammatory agents (NSAIDs), COX-2 inhibitors, COX-3 inhibitors, opioids, inhibitors/antagonists of IL-1, inhibitors/antagonists of TNF-alpha, inhibitors of matrix metallo-proteinases (MMPs), cathepsin K inhibitors, inhibitors/antagonists of RANK-ligand, statins, glucocorticoids, chondroitin sulphate, NMDA receptor antagonists, inhibitors of interleukin-I converting enzyme, Calcitonin gene related peptide antagonists, glycine antagonists, vanilloid receptor antagonists, inhibitors of inducible nitric oxide synthetase (iNOS), N-acetylcholine receptor agonists, neurokinin antagonists, neuroleptic agents, PAR2 receptor antagonists and anabolic growth factors acting on joint tissue components. Pharmaceutical compositions comprising a strontium-containing compound and a second therapeutically and/or prophylactically active substance as defined above.

    摘要翻译： 改善关节疾病的治疗，例如， 骨关节炎和类风湿性关节炎以及疼痛，其中单独施用含锶化合物或与一种或多种第二治疗和/或预防活性物质组合施用，所述第二治疗和/或预防活性物质选自二膦酸盐，葡糖胺，扑灭剂，止痛剂，疾病 修饰抗风湿化合物（DMARD），选择性雌激素受体调节剂（SERM），芳香酶抑制剂，非甾体抗炎药（NSAID），COX-2抑制剂，COX-3抑制剂，阿片样物质，IL-1抑制剂/拮抗剂 ，TNF-α的抑制剂/拮抗剂，基质金属蛋白酶（MMPs）的抑制剂，组织蛋白酶K抑制剂，RANK-配体的抑制剂/拮抗剂，他汀类，糖皮质激素，硫酸软骨素，NMDA受体拮抗剂，白细胞介素-I转化酶抑制剂， 降钙素基因相关肽拮抗剂，甘氨酸拮抗剂，香草素受体拮抗剂，诱导型一氧化氮合成酶抑制剂（iNOS），N-乙酰 胆碱受体激动剂，神经激肽拮抗剂，精神抑制剂，PAR2受体拮抗剂和作用于关节组织成分的合成代谢生长因子。 包含含锶化合物和如上定义的第二治疗和/或预防活性物质的药物组合物。